SYNTEX, DuPONT ARE FIRST CLIENTS OF NEW HEALTH CARE CONSULTING FIRM
Executive Summary
SYNTEX, DuPONT ARE FIRST CLIENTS OF NEW HEALTH CARE CONSULTING FIRM, Riddiough & Associates, according to the firm's founder, Michael Riddiough, PharmD. In an April 11 press release announcing its formation, Riddough & Associates said its aim is "to aid the health care industry -- particularly the pharmaceutical, diagnostic, and medical device mfrs. -- analyze the impact of political, economic, and consumer trends on future business." The firm said its "mainstay" activity is cost-effectiveness analyses of various health care technologies both within and among various categories. "Riddiough & Associates offers . . . analyses of emerging health care markets, cost-effectiveness studies, political analyses, govt. relations, market strategies, and issues management for clients with specific problems," the release states. Riddiough was formerly policy studies director for the Pharmaceutical Mfrs. Assn. (PMA). Before joining the assn., he was senior health analyst for the Congressional Office of Technology Assessment. He joined Syntex after leaving PMA. One feature of Riddiough & Associates is its establishment of a consortium of firms to offer clients expertise in a variety of fields. "To expand its scope of services," the consulting firm said, Riddiough & Associates "has assembled a consortium of firms with experts in a range of fields, including public health, reimbursement, health law, environmental forecasting, market research and marketing, clinical therapeutics, federal relations, and public relations." Consortium firms, the release continues, include Vince Gardner & Associates (headed by the former Natl. Assn. of Chain Drug Stores VP-health programs), ECI Associates, SysteMetrics Inc. (Santa Barbara, Calif.), Alternative Futures Associates, Lewin & Associates, and Pharmacotherapy Consultants.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth